Executive Profile

Barry C. Buckland Ph.D. Co-Founder, Co-Chairman of The Scientfic Advisory Board and Director, Enumeral Biomedical Corp.

Age	Total Calculated Compensation	This person is connected to 2 Board Members in 2 different organizations across 3 different industries. See Board Relationships
--	--

Background

Mr. Barry C. Buckland, Ph.D. Co-founded Enumeral Biomedical Corp. in 2009 and serves as its Co-Chairman of The Scientfic Advisory Board. Mr. Buckland serves as Head of BioProcess Development at Protein Sciences Corporation. Mr. Buckland has been the Chief Executive Officer of BiologicB LLC since 2009. He is a Technical Advisor at Hilleman Laboratories (Joint venture between Wellcome Trust and Merck & Co, Inc). Dr. Buckland joined Protein Sciences in 2011 after a 29-year ... career at Merck Research Laboratories, including 16 years as Vice President of Bioprocess R&D, during which time vaccines were licensed against chicken pox, shingles, HPV, hepatitis A and rotavirus. He served as Vice President of Merck & Co., USA and Merck & Co.Inc. He is an experienced International expert for the Development of Biologic products with a special focus on vaccines and Therapeutic proteins. He has been a Director of Ancora Pharmaceuticals Inc. since February 2010 and serves as a Member of Scientific Advisory Board. He serves as a Director of Mucosis BV He serves as Director of Enumeral Biomedical Corporation. He serves as Chair and member of Board of Directors at Engineering Conferences International (ECI). He has been Visiting Professor, Dept of Biochemical Engineering at University College London since 1995. He chaired two ECI International Conferences on Cell Culture (Cell Cuture Engeneering IV and V), Co Chaired the first three ECI International Conferences on Metabolic Engineering and Co-Chaired the first three ECI International Conferences on Vaccine Technology. He has received numerous awards recognizing his contributions throughout his career and is a member of the prestigious USA National Academy of Engineering (NAE). He was also recognized by the American Institute of Chemical Engineers as one of the top 100 Chemical Engineers during the past 60 years. He was elected as Fellow in University College of London in 1998 and member of National Academy of Engineering in 1997. He honoured the Discoverers Award for the development of a vaccine effective against HPV and Cervical Cancer (GARDASIL) by The Pharmaceutical Research and Manufacturers of America (PhRMA) in 2009, named as one of the "One Hundred Chemical Engineers of the Modern Era" as part of the AIChE Centennial celebration in Philadelphia by American Institute of Chemical Engineering (AIChE) in 2008, Marvin Johnson Award for Lifetime Achievement in Biotechnology by American Chemical Society (ACS) in 2008, Award for leading process development for licensure of four new vaccines by Merck & Co, Inc., Board of Directors in 2007 and UK Institute of Chemical Engineering, Donald Medal for outstanding contributions to Biotechnology in 2002. He has over 60 publications in Peer reviewed journals. Mr. Buckland holds PhD in Biochemical Engineering at University College London, in 1974. He has a B.Sc. in Chemical Engineering from the University of Manchester, UK and a M.Sc.

Corporate Headquarters 1450 Broadway New York, New York 10018 United States Phone: 617-945-9146 Fax: 617-945-9148 Board Members Memberships Co-Founder, Co-Chairman of The Scientfic Advisory Board and Director Enumeral Biomedical Corp. 2010-Present Director and Member of Scientific Advisory Board Ancora Pharmaceuticals, Inc. Education BS University of Manchester PhD 1974 University College London Other Affiliations Protein Sciences Corporation University of Manchester University College London Ancora Pharmaceuticals, Inc.

Annual Compensation There is no Annual Compensation data available. Stocks Options There is no Stock Options data available. Total Compensation There is no Total Compensation data available.

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.